CliffBio
small molecule

LORAZEPAM

LORAZEPAM

Loss of exclusivity—loss of exclusivity
CompanyPar →See this company's full patent-cliff portfolio

Drug detail

Brand nameLORAZEPAM
Active ingredientLORAZEPAM
Strength2MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 1986
Marketing statusDISCN

More from Par

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

LORAZEPAM patent cliff — loss of exclusivity — | CliffBio